PRNewsWire
11 Nov 2025, 01:30 UTC · 45w ago
Verdict
Headline leans bearish. We score QURE −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA notified uniQure that data for its Huntington's disease gene therapy, AMT-130, is insufficient to support a Biologics License Application (BLA) submission.
More negative than 99% of claims this week
The timing for the BLA submission for AMT-130 is now unclear following the FDA's feedback.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
Law firm Kessler Topaz Meltzer & Check is investigating potential federal securities law violations by uniQure.
More negative than 78% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company's stock fell over 50% after the FDA indicated that data for its Huntington's disease therapy was insufficient for BLA submission, leading to a legal investigation.
More negative than 85% of ticker scores this week
The company is the subject of a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
+46.5%
Price is moving against the score
$38.32 vs $26.15 close before publication (Nov 10) · not market-adjusted
QURE chart →
